Yoshinobu Onuma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yoshinobu Onuma has a total of 273 co-authors. Here are the top co-authors by number of shared publications:
Patrick W. Serruys
18 shared publications- Yohei Sotomi
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine
16 shared publications - Roberto Diletti
Department of (Interventional) Cardiology, Thoraxcenter Erasmus University Medical Center Rotterdam The Netherlands
15 shared publications - Robert-Jan van Geuns
Department of Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands
13 shared publications Patrick Serruys
11 shared publicationsPatrick W.J.C. Serruys
10 shared publications
Latest Publications
- 1 August 2018
- Published by AME Publishing Company in ASVIDE
- Vol. 5, 657
Syntax II and Syntax III trials: what is the take home message for surgeons? Lessons learned from the 2 year results of Syntax II
- 1 August 2018
- Published by AME Publishing Company in ASVIDE
- Vol. 5, 657
Syntax II and Syntax III trials: what is the take home message for surgeons? Lessons learned from the 2 year results of Syntax II
- 1 August 2018
- Published by AME Publishing Company in ASVIDE
- Vol. 5, 658
Syntax II and Syntax III trials: what is the take home message for surgeons? The Syntax III trial
- 1 August 2018
- Published by AME Publishing Company in ASVIDE
- Vol. 5, 658
Syntax II and Syntax III trials: what is the take home message for surgeons? The Syntax III trial
- Open Access
- 9 May 2018
- Published by IntechOpen
Multimodality Imaging to Detect Vulnerable Plaque in Coronary Arteries and Its Clinical Application
Postmortem studies have described the association between the thin-cap fibroatheroma (TCFA) and the occurrence of acute coronary syndrome (ACS). Both noninvasive and invasive techniques have been refined and used as a research tool to visualize the plaque at a high risk of disruption. There has been a considerable effort to develop the imaging modalities that offer detailed visualization of coronary pathology and accurately predict the adverse cardiac outcomes. This chapter provides an overview of the current and experimental coronary imaging methods to detect vulnerable plaque and discuss the potential implication of multimodality imaging in clinical practice.
- 9 May 2018
- Published by IntechOpen
Open AccessMultimodality Imaging to Detect Vulnerable Plaque in Coronary Arteries and Its Clinical Application
Postmortem studies have described the association between the thin-cap fibroatheroma (TCFA) and the occurrence of acute coronary syndrome (ACS). Both noninvasive and invasive techniques have been refined and used as a research tool to visualize the plaque at a high risk of disruption. There has been a considerable effort to develop the imaging modalities that offer detailed visualization of coronary pathology and accurately predict the adverse cardiac outcomes. This chapter provides an overview of the current and experimental coronary imaging methods to detect vulnerable plaque and discuss the potential implication of multimodality imaging in clinical practice.
- Open Access
- 1 December 2017
- Published by Elsevier in International Journal of Cardiology
- Vol. 249, 119-126
Impact of calcium on procedural and clinical outcomes in lesions treated with bioresorbable vascular scaffolds - A prospective BRS registry study
- 1 December 2017
- Published by Elsevier in International Journal of Cardiology
- Vol. 249, 119-126
Open AccessImpact of calcium on procedural and clinical outcomes in lesions treated with bioresorbable vascular scaffolds - A prospective BRS registry study
- 2 October 2017
- Published by Taylor & Francis
- p. 491-493
Emerging technologies: Overview of the field
Bioresorbable scaffolds offer the possibility of transient scaffolding of the vessel to prevent acute vessel closure and recoil while also transiently eluting an antiproliferative drug to counteract the constrictive remodeling and excessive neointimal hyperplasia. The concept of a transient coronary device that disappears after doing its job fits the physiological demand to restore the vessel structure and seems attractive both to physicians and patients. Following the successful and intriguing findings observed in the first-in-human trials, the four products, Absorb, Desolve, ART, and Magmaris scaffolds succeeded to acquire a CE mark.
- 2 October 2017
- Published by Taylor & Francis
- p. 491-493
Emerging technologies: Overview of the field
Bioresorbable scaffolds offer the possibility of transient scaffolding of the vessel to prevent acute vessel closure and recoil while also transiently eluting an antiproliferative drug to counteract the constrictive remodeling and excessive neointimal hyperplasia. The concept of a transient coronary device that disappears after doing its job fits the physiological demand to restore the vessel structure and seems attractive both to physicians and patients. Following the successful and intriguing findings observed in the first-in-human trials, the four products, Absorb, Desolve, ART, and Magmaris scaffolds succeeded to acquire a CE mark.
- 2 October 2017
- Published by Taylor & Francis
- p. 207-214
What are appropriate clinical endpoints? From device failure assessment to angina evaluation
- 2 October 2017
- Published by Taylor & Francis
- p. 207-214
What are appropriate clinical endpoints? From device failure assessment to angina evaluation
- 2 October 2017
- Published by Taylor & Francis
- p. 444-461
Acute scaffold disruption and late discontinuities
- 2 October 2017
- Published by Taylor & Francis
- p. 444-461
Acute scaffold disruption and late discontinuities
- 2 October 2017
- Published by Taylor & Francis
- p. 124-133
Quantitative coronary angiography of bioresorbable vascular scaffold: A core lab perspective
- 2 October 2017
- Published by Taylor & Francis
- p. 124-133
Quantitative coronary angiography of bioresorbable vascular scaffold: A core lab perspective
- 2 October 2017
- Published by Taylor & Francis
- p. 316-318
The Mirage microfiber sirolimus eluting coronary scaffold
- 2 October 2017
- Published by Taylor & Francis
- p. 316-318
The Mirage microfiber sirolimus eluting coronary scaffold